Press Releases

Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds

WATERTOWN, Mass. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has signed an agreement with a major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary

WATERTOWN, Mass. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2017

Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call and Webcast Today, September 11th , at 4:30 p.m. ET WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained

WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual

WATERTOWN, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report results for its fourth quarter and fiscal year ended June 30, 2017 on Monday,

WATERTOWN, Mass. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker , President and Chief Executive Officer, will present at the

WATERTOWN, Mass. , July 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that three abstracts supporting the Company's Durasert™ three-year treatment for posterior segment uveitis

WATERTOWN, Mass. , July 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences, Inc.

WATERTOWN, Mass. , June 28, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peterson , a seasoned healthcare executive has been elected to the Company's Board of

WATERTOWN, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market

Highly Significant Difference Observed Between Durasert and Control Group  in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass. , June 13, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of

Positive Data Presented at the Association for Research in Vision and Ophthalmology Annual Meeting pSivida Anticipates Reporting Top Line Results from the Second Pivotal Phase 3 Clinical Trial in June 2017 WATERTOWN, Mass. , May 08, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.

 EU and US Calendar 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Schedule Conference Call and Webcast Today, May 4th , at 4:30 p.m. ET WATERTOWN, Mass. , May 04, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development

WATERTOWN, Mass. , April 19, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the third quarter of fiscal year 2017 will be released

WATERTOWN, Mass. , March 15, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company's Durasert three-year treatment for posterior segment uveitis has

WATERTOWN, Mass. , Feb. 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the company and its progress

EU and U.S. 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Track Conference Call and Webcast Today, February 7 , at 4:30 p.m. ET WATERTOWN, Mass. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of

WATERTOWN, Mass. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the second quarter of fiscal year 2017 will be released

WATERTOWN, Mass. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced that Deb Jorn , a proven business development executive, has joined the Company as Executive Vice President of